AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Wave Life Sciences Ltd. Director's Dealing 2024

Nov 14, 2024

31900_dirs_2024-11-13_6ee0c7e9-ef07-4325-af65-8ecd4b8bed2f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2024-11-08

Reporting Person: Francis Chris (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-08	Ordinary Shares	M	36000	$8.17	Acquired	36000	Direct
2024-11-08	Ordinary Shares	S	36000	$16	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-11-08	Share Option (right to buy)	$8.17	M	36000	Disposed	2030-03-03	Ordinary Shares (36000)	Direct

Footnotes

F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.

F2: The share options that were exercised in this reportable transaction were fully vested.